首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe
【2h】

In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe

机译:最近在欧洲获得的特拉万星对革兰氏阳性临床分离株的体外活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC50 and MIC90) were both 0.25 μg/ml, irrespective of methicillin resistance. MIC50 and MIC90 were 0.25 and 0.5 μg/ml for vancomycin-susceptible enterococci and 1 and 2 μg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by ≤0.12 μg/ml.
机译:替拉万星的体外活性针对620克阳性分离株进行了测试。对于葡萄球菌,不论甲氧西林耐药性如何,抑制50%和90%分离株(MIC50和MIC90)的MIC均为0.25μg/ ml。万古霉素易感肠球菌的MIC50和MIC90分别为0.25和0.5μg/ ml,耐万古霉素的肠球菌的MIC50和MIC90为1和2μg/ ml。肺炎链球菌,A组和B组β-溶血性链球菌和绿藻类链球菌的抑制作用≤0.12μg/ ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号